Jin Rong Jie·2025-05-27 05:19Group 1 - The core viewpoint of the articles highlights the positive performance of the Hong Kong innovative drug sector, with the Hong Kong Innovative Drug 50 ETF (513780) rising nearly 32% year-to-date as of May 27, 2025, and individual stocks like Junshi Bioscience and Lepu Biopharma showing significant gains [1][2] - The upcoming ASCO annual meeting, scheduled from May 30 to June 3, 2025, in Chicago, is noted as a major event for the oncology field, with numerous domestic innovative drug companies showcasing impressive clinical data and a record number of original research presentations from Chinese experts [1] - The current valuation of growth-oriented pharmaceutical companies is favorable, with most having a PEG ratio below 1, indicating a potential for both earnings and valuation growth in the pharmaceutical sector [2] Group 2 - The top ten constituents of the CSI Hong Kong Innovative Drug Index account for 71.6% of the index, including high-quality A-share companies like Innovent Biologics and CSPC Pharmaceutical Group, all involved in innovative drug research and development [2] - The domestic innovative drug sector is at a new historical starting point, with companies enhancing their competitiveness and expanding internationally, supported by rapid revenue growth and favorable policies [2]